A detailed history of Susquehanna International Group, LLP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 64,661 shares of DAWN stock, worth $860,637. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,661
Previous 91,098 29.02%
Holding current value
$860,637
Previous $1.26 Million 28.29%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.72 - $16.03 $336,278 - $423,785
-26,437 Reduced 29.02%
64,661 $900,000
Q2 2024

Aug 15, 2024

BUY
$12.03 - $17.69 $203,836 - $299,739
16,944 Added 22.85%
91,098 $1.26 Million
Q1 2024

May 07, 2024

BUY
$13.56 - $17.46 $363,082 - $467,508
26,776 Added 56.52%
74,154 $1.23 Million
Q4 2023

Feb 14, 2024

SELL
$9.68 - $15.37 $71,225 - $113,092
-7,358 Reduced 13.44%
47,378 $691,000
Q3 2023

Nov 14, 2023

SELL
$11.22 - $14.86 $284,247 - $376,463
-25,334 Reduced 31.64%
54,736 $671,000
Q2 2023

Aug 11, 2023

SELL
$11.74 - $14.47 $248,981 - $306,879
-21,208 Reduced 20.94%
80,070 $956,000
Q1 2023

May 16, 2023

BUY
$12.75 - $23.41 $1.03 Million - $1.89 Million
80,710 Added 392.41%
101,278 $1.35 Million
Q4 2022

Feb 14, 2023

SELL
$18.77 - $22.0 $540,576 - $633,600
-28,800 Reduced 58.34%
20,568 $442,000
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $811,609 - $1.31 Million
49,368 New
49,368 $989,000
Q1 2022

May 16, 2022

BUY
$9.12 - $17.47 $169,668 - $325,011
18,604 New
18,604 $185,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $978M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.